Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Current Advances in Diagnostic and Therapeutic Approaches for Gastric Cancer
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Current Advances in Diagnostic and Therapeutic Approaches for Gastric Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 15 May 2024 | Viewed by 1236

Special Issue Editor

Dr. Diana Noronha Nunes

E-Mail Website
Guest Editor
Laboratory of Medical Genomics, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil
Interests: use of genomics tools; evaluation of cancer diagnosis and prognosis biomarkers; evaluation of liquid biopsy components; tumor associated microbiota

Special Issue Information

Dear Colleagues,

Patients with gastric adenocarcinoma (GA) are commonly diagnosed with advanced disease, since the most common symptoms are generally non-specific, such as dyspepsia, heartburn, indigestion, anemia, and weight loss, among others. Additionally, a significant number of patients are asymptomatic. The gold-standard test for GA diagnosis is upper endoscopy with biopsy collection, which is an invasive procedure with implied intrinsic risks. Most patients will be subjected to therapeutic regimens combining chemotherapy with surgery and in some cases also immunotherapy, without knowing which of them will respond to treatment.

This Special Issue welcomes manuscripts presenting:

  • Non-invasive and less-invasive methodologies for gastric cancer diagnosis, staging and prognosis, including but not restricted to liquid and breath biopsies and digital pathology and imaging. Additionally, we welcome papers on the evaluation of patients at risk of developing gastric cancer or prone to developing gastric malignancy due to history of familial disease.
  • Methodologies or biomarkers to determine patients’ response to gastric cancer treatment modalities (neoadjuvant and adjuvant chemotherapies, surgical or immunotherapies).
  • Artificial intelligence algorithms, or other digital tools, supporting the identification of clinically relevant patterns from a patient’s images and metadata, such as tumor aggressiveness, toxicity to treatment, response to treatment, etc.

Dr. Diana Noronha Nunes
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastric cancer
  • non-invasive diagnostic methodologies
  • biomarkers
  • artificial intelligence
  • digital pathology
  • response to treatment

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 5213 KiB  
Communication
Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the MET Gene: Doublet Treatment versus Single Agent Treatment
by Sung-Hwa Sohn, Hee Jung Sul, Bum Jun Kim and Dae Young Zang
Int. J. Mol. Sci. 2024, 25(3), 1769; https://doi.org/10.3390/ijms25031769 - 1 Feb 2024
Viewed by 854
Abstract
Although conventional combination chemotherapies for advanced gastric cancer (GC) increase survival, such therapies are associated with major adverse effects; more effective and less toxic treatments are required. Combinations of different anti-cancer drugs, for example, paclitaxel plus ramucirumab, have recently been used as second-line [...] Read more.
Although conventional combination chemotherapies for advanced gastric cancer (GC) increase survival, such therapies are associated with major adverse effects; more effective and less toxic treatments are required. Combinations of different anti-cancer drugs, for example, paclitaxel plus ramucirumab, have recently been used as second-line treatments for advanced GC. This study evaluated how copy number variations of the MET gene, MET mutations, and MET gene and protein expression levels in human GC cells modulate the susceptibility of such cells to single-agent (tepotinib, ramucirumab, or paclitaxel) and doublet (tepotinib-plus-paclitaxel or ramucirumab-plus-paclitaxel treatment regimens. Compared with ramucirumab-plus-paclitaxel, tepotinib-plus-paclitaxel better inhibited the growth of GC cells with MET exon 14 skipping mutations and those lacking MET amplification but containing phosphorylated MET; such inhibition was dose-dependent and associated with cell death. Tepotinib-plus-paclitaxel and ramucirumab-plus-paclitaxel similarly inhibited the growth of GC cells lacking MET amplification or MET phosphorylation, again in a dose-dependent manner, but without induction of cell death. However, tepotinib alone or tepotinib-plus-ramucirumab was more effective against c-MET-positive GC cells (>30 copy number variations) than was ramucirumab or paclitaxel alone or ramucirumab-plus-paclitaxel. These in vitro findings suggest that compared with ramucirumab-plus-paclitaxel, tepotinib-plus-paclitaxel better inhibits the growth of c-MET-positive GC cells, cells lacking MET amplification but containing phosphorylated MET, and cells containing MET mutations. Clinical studies are required to confirm the therapeutic effects of these regimens. Full article
(This article belongs to the Special Issue Current Advances in Diagnostic and Therapeutic Approaches for Gastric Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop